吉利德科學 GILD 深 滬
等待開盤 01-30 09:30:00 美东时间
140.20
+0.480
+0.34%
華盛通- 最 高140.51
- 今 開139.75
- 成交量 173.38万股
- 最 低 138.935
- 昨 收 139.72
- 總市值 1739.88亿
- 52周最高 141.71
- 市盈率 靜 366.54
- 換手率 0.14%
- 52周最低 91.00
- 委 比 -85.19%
- 總股本 12.41亿
- 歷史最高 141.71
- 量 比 0.62
- 振 幅 1.13%
- 歷史最低 6.72
- 每 手 1
- 風險率 9.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美国联邦医保将新增15种药物价格谈判
美国联邦医疗保险和医疗补助服务中心（Centers for Medicare and Medicaid Services，CMS）在其价格谈判计划中新增1...
01-29 00:19
BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Seagate, Nextpower
BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Seagate, Nextpower Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures rose on Wednesday, helped by gains in chip
01-28 20:05
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
Demystifying Gilead Sciences: Insights From 17 Analyst Reviews
17 analysts have expressed a variety of opinions on Gilead Sciences (NASDAQ:GIL...
01-28 05:01
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
Gilead Sciences Announces That The New England Journal Of Medicine Published The Full Results From The Phase 3 ASCENT-04/KEYNOTE-D19 Study; ASCENT-04 Met Its Primary Endpoint Of Progression-free Survival With A 35% Reduced Risk Of Disease Progression Or Death
Gilead Sciences, Inc. (NASDAQ:GILD) today announced The New England Journal of Medicine(NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy®
01-22 06:07
Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC
Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC Gilead Sciences Inc. announced the publication of full results from the Phase 3 ASCENT-04/KEYNOTE-D19 clinical trial in The New England Journal of Medicine. The study evaluated the efficacy and sa
01-22 06:00
Gilead Sciences Director Jeffrey Bluestone Reports Disposal of Common Shares
Gilead Sciences Director Jeffrey Bluestone Reports Disposal of Common Shares Jeffrey Bluestone, Director at Gilead Sciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technol
01-22 05:26
Looking Into Gilead Sciences Inc's Recent Short Interest
Gilead Sciences Inc's (NYSE:GILD) short interest as a percent of float has rise...
01-17 02:00
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
